Global Graft Versus Host Disease Gvhd Treatment Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 3.94 Billion |
 Taille du marché (année de prévision) |
USD 5.50 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché mondial du traitement de la maladie du greffon contre l'hôte (GvHD), par traitement (médicament et thérapie), type (GvHD chronique, GvHD aiguë et prophylactique), sexe (femme et homme), âge (adultes et pédiatriques), mode d'administration (oral, intraveineux, topique et autres), utilisateur final (hôpitaux, centres de transplantation, instituts et centres spécialisés), canal de distribution (appel d'offres direct, vente au détail et autres - Tendances et prévisions de l'industrie jusqu'en 2031.
Analyse et perspectives du marché du traitement de la maladie du greffon contre l'hôte (GvHD)
Français Selon un article publié par les National Institutes of Health en août 2023, selon l'étude menée dans 24 centres HCT en Amérique du Nord, en Europe et en Asie pour étudier la progression naturelle de la GvHD, l'incidence totale de la GvHD aiguë nécessitant un traitement était de 40,9 %, 35,2 % pour la GvHD aiguë classique et 5,7 % pour la GvHD aiguë tardive. Parmi les patients atteints de GvHD aiguë classique et tardive, 77,8 % (1245 sur 1601) et 75,4 % (193 sur 256), respectivement, ont reçu un traitement systémique contre la GvHD. Selon un article publié par la National Library of Medicine, la maladie du greffon contre l'hôte (GvHD) aiguë peut se développer chez environ la moitié des patients subissant une transplantation de cellules souches hématopoïétiques (HCT) provenant d'un frère ou d'une sœur compatible avec l'antigène leucocytaire humain (HLA).
Data Bridge Market Research analyse que le marché mondial du traitement de la maladie du greffon contre l'hôte (GvHD) devrait atteindre 5,50 milliards USD d'ici 2031, contre 3,94 milliards USD en 2023, avec un TCAC de 4,4 % au cours de la période de prévision de 2024 à 2031.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Années historiques |
2022 (personnalisable pour 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en milliards USD |
|
Segments couverts |
Traitement (médicaments et thérapie), type (GvHD chronique, GvHD aiguë et prophylactique), sexe (femme et homme), âge (adultes et enfants), mode d'administration (oral, intraveineux, topique et autres), utilisateur final (hôpitaux, centres de transplantation, instituts et centres spécialisés), canal de distribution (appel d'offres direct, vente au détail et autres) |
|
Pays couverts |
États-Unis, Canada, Mexique, Allemagne, France, Italie, Royaume-Uni, Espagne, Belgique, Russie, Suisse, Danemark, Reste de l'Europe, Chine, Japon, Australie, Corée du Sud, Inde, Malaisie, Singapour, Philippines, Indonésie, Reste de l'Asie-Pacifique, Brésil, Argentine, Reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Koweït, Bahreïn et Reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Janssen Global Services, LLC, MALLINCKRODT PLC, Incyte., Sanofi, Alkem Laboratories Ltd. et Astellas Pharma Inc., entre autres |
Définition du marché
La maladie du greffon contre l'hôte (GvHD) est une maladie qui peut survenir après une greffe de cellules souches ou de moelle osseuse, au cours de laquelle les cellules du donneur nouvellement transplantées attaquent le corps du receveur. Cette réponse immunitaire peut provoquer divers symptômes et complications, allant de légers à graves. La GvHD est une préoccupation majeure en médecine de transplantation et nécessite une gestion prudente.
Le traitement de la maladie du greffon contre l'hôte (GvHD) fait référence aux différentes interventions médicales utilisées pour gérer et soulager les symptômes de la maladie. Ces traitements visent à supprimer la réponse immunitaire des cellules du donneur contre les tissus et les organes du receveur. Les traitements courants de la maladie du greffon contre l'hôte comprennent des médicaments immunosuppresseurs, tels que les corticostéroïdes, ainsi que d'autres médicaments qui ciblent des aspects spécifiques de la réponse immunitaire. Dans les cas graves, des thérapies plus intensives, telles que la photophérèse ou d'autres thérapies immunomodulatrices, peuvent être utilisées. Le choix du traitement dépend de la gravité de la maladie du greffon contre l'hôte et d'autres facteurs spécifiques à chaque patient.
Dynamique du marché mondial du traitement de la maladie du greffon contre l'hôte (GvHD)
Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteur
- Augmentation de l'incidence des greffes de cellules souches hématopoïétiques (GCSH)
L'augmentation du nombre de greffes de cellules souches hématopoïétiques (GCSH) est un facteur important de la demande de traitement de la maladie du greffon contre l'hôte (GvHD). Cette tendance est principalement alimentée par la prévalence croissante des cancers du sang, tels que la leucémie, le lymphome et le myélome, qui nécessitent souvent une GCSH comme option de traitement. En outre, d'autres troubles hématologiques, tels que l'anémie aplasique et certains troubles génétiques, nécessitent également une GCSH pour la prise en charge de la maladie.
Le nombre de patients subissant une greffe de cellules souches hématopoïétiques (GCSH) ne cesse d'augmenter, tout comme la demande de traitement efficace contre la GvHD. La GvHD est une complication courante de la greffe de cellules souches hématopoïétiques (GCSH), qui survient lorsque les cellules transplantées du donneur attaquent les tissus du receveur, entraînant des symptômes potentiellement graves et potentiellement mortels. Par conséquent, l'incidence croissante de la greffe de cellules souches hématopoïétiques (GCSH) se traduit directement par un besoin accru de traitement contre la GvHD pour gérer et atténuer les effets de cette complication.
Retenue
- Coût élevé des médicaments et des soins de soutien
Le coût élevé du traitement de la maladie du greffon contre l'hôte (GvHD) représente une contrainte qui va au-delà de la simple accessibilité des médicaments. Il englobe les dépenses associées aux soins complets, notamment les médicaments, les hospitalisations, les consultations externes, les tests diagnostiques et les thérapies de soutien. Dans les régions en développement où les ressources en matière de soins de santé sont limitées et où les contraintes financières sont fortes, ces coûts peuvent être particulièrement lourds, entraînant souvent des retards ou des traitements inadéquats.
Calcineurin inhibitors, such as tacrolimus and cyclosporine, are vital components of GvHD treatment, but their high prices can strain healthcare budgets. Antimetabolites like methotrexate and mycophenolate mofetil, immunosuppressive agents such as ruxolitinib, belumosudil, and ibrutinib, and corticosteroids including methylprednisolone and prednisolone are also essential but put excessive economic burden on patients.
Opportunity
- Market Expansion through Strategic Initiatives and Partnership
Market expansion through strategic collaboration can be a highly effective approach for companies operating in the GvHD (Graft-versus-Host Disease) treatment market. As the demand for innovative treatments and comprehensive care solutions for GvHD continues to rise, companies can capitalize on strategic partnerships and collaborations to expand their market presence and offer a diverse product portfolio tailored to meet evolving patient needs .By collaborating with research institutions, academic centers, and biotechnology companies, GvHD market players can access cutting-edge technologies, novel therapeutic approaches, and scientific expertise to advance their product development efforts. These collaborations enable companies to accelerate the discovery and development of promising GvHD therapies, including personalized cellular therapies, targeted biologic agents, and supportive care interventions. Moreover, strategic alliances with key opinion leaders and patient advocacy groups facilitate market access and enhance the adoption of new treatments by fostering trust, credibility, and patient engagement.
Furthermore, market expansion through strategic initiatives allows GvHD market players to diversify their product portfolio and capture a larger share of the GvHD market. By leveraging their expertise and resources to develop complementary products and services, companies can offer comprehensive care solutions that address the multifaceted needs of GvHD patients across different stages of the disease continuum.
Challenge
- Stringent Regulations in GvHD Therapies
Stringent regulation presents a significant challenge for the GvHD market in the future. As the field continues to advance with the development of novel therapies and treatment modalities, regulatory authorities impose rigorous standards for safety, efficacy, and quality control. Meeting these regulatory requirements demands substantial investment in preclinical and clinical development, as well as extensive documentation and data submission for regulatory approval. Additionally, the complexity of GvHD, its heterogeneous presentation, and the lack of standardized diagnostic criteria further complicate regulatory evaluation and approval processes. Regulatory agencies often require robust clinical trial data demonstrating not only the efficacy of novel therapies but also their comparative effectiveness against existing treatments. This necessitates large-scale, well-designed clinical trials with lengthy follow-up periods, leading to prolonged timelines and increased costs for product development.
Recent Developments
- In March 2024, Johnson & Johnson has announced the successful completion of its acquisition of Ambrx Biopharma, Inc. This clinical-stage biopharmaceutical company possesses a proprietary synthetic biology technology platform used for designing and developing next-generation antibody drug conjugates (ADCs). This acquisition offers Johnson & Johnson a unique opportunity to create, develop, and market targeted oncology therapies
- In February 2024, AbbVie Inc. and Tentarix Biotherapeutics have announced a partnership to collaboratively discover and develop conditionally-active, multi-specific biologics in the fields of oncology and immunology. This collaboration will leverage AbbVie's extensive experience in these areas alongside Tentarix's proprietary Tentacles™ platformIn April 2023, Medtronic and DaVita Inc. jointly launched Mozarc Medical, an independent company dedicated to transforming kidney health and advancing patient-centered technology solutions
- In February 2024, Novartis AG has agreed to acquire MorphoSys AG, a German biopharmaceutical company focused on innovative oncology medicines. This acquisition, subject to standard closing conditions and regulatory approvals, strengthens Novartis' oncology pipeline and expands its global presence in hematology
- In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients for GvHD by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
- In January 2020, Astellas Pharma Inc. announced that it has entered into an agreement with Adaptimmune to develop stem cell derived allogenc CAR-T and TCR T-Cell Therapies to treat cancer. This will help the company to further acquire the market in coming years
Global Graft-Versus-Host Disease (GvHD) Treatment Market Scope
Le marché mondial du traitement de la maladie du greffon contre l'hôte (GvHD) est segmenté en sept segments notables en fonction du traitement, du type, du sexe, de l'âge, de la méthode d'administration, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences entre vos marchés cibles.
Traitement
- Médicament
- Thérapie
Sur la base du traitement, le marché est segmenté en médicaments et en thérapie.
Taper
- GvHD chronique
- GvHD aiguë
- Prophylactique
Sur la base du type, le marché est segmenté en GvHD chronique, GvHD aiguë et prophylactique.
Genre
- Femelle
- Mâle
Sur la base du sexe, le marché est segmenté en femmes et en hommes.
Âge
- Adultes
- Pédiatrique
En fonction de l’âge, le marché est segmenté en adultes et enfants.
Mode d'administration
- Oral
- Intraveineux
- Topique
- Autres
Sur la base du mode d’administration, le marché est segmenté en voie orale, intraveineuse, topique et autres.
Utilisateur final
- Hôpitaux
- Centres de transplantation
- Instituts
- Centres spécialisés
Sur la base de l’utilisateur final, le marché est segmenté en hôpitaux, centres de transplantation, instituts et centres spécialisés.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
- Autres
Sur la base du canal de distribution, le marché est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché mondial du traitement de la maladie du greffon contre l'hôte (GvHD)
Le marché mondial du traitement de la maladie du greffon contre l’hôte (GvHD) est segmenté en sept segments notables en fonction du traitement, du type, du sexe, de l’âge, de la méthode d’administration, de l’utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada, le Mexique, l'Allemagne, la France, l'Italie, le Royaume-Uni, l'Espagne, la Belgique, la Russie, la Suisse, le Danemark, le reste de l'Europe, la Chine, le Japon, l'Australie, la Corée du Sud, l'Inde, la Malaisie, Singapour, les Philippines, l'Indonésie, le reste de l'Asie-Pacifique, le Brésil, l'Argentine, le reste de l'Amérique du Sud, l'Afrique du Sud, l'Arabie saoudite, les Émirats arabes unis, le Koweït, Bahreïn et le reste du Moyen-Orient et de l'Afrique.
Français L'Amérique du Nord devrait dominer le marché en raison de son infrastructure de soins de santé avancée, de ses taux élevés de greffes de cellules hématopoïétiques, de ses investissements importants dans la recherche et le développement, de son environnement réglementaire favorable, de ses dépenses de santé importantes et d'une plus grande sensibilisation à la maladie. Ces facteurs contribuent à la position de leader de la région dans le développement et l'adoption de nouveaux traitements contre la GvHD. Les États-Unis devraient dominer l'Amérique du Nord en raison de l'incidence croissante des greffes de cellules souches hématopoïétiques (GCSH). Le Japon devrait dominer la région Asie-Pacifique en raison de sa technologie médicale avancée, de ses investissements importants dans la recherche et le développement dans le domaine des soins de santé, d'un taux élevé de greffes de cellules hématopoïétiques, d'un soutien gouvernemental fort et d'une efficacité réglementaire dans l'approbation de nouveaux traitements, ainsi que d'une sensibilisation et d'une éducation accrues du public sur la GvHD. L'Allemagne devrait dominer la région Europe en raison de son adoption de technologies avancées, de sa solide infrastructure de soins de santé et de son marché mature.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du traitement mondial de la maladie du greffon contre l'hôte (GvHD)
Le paysage concurrentiel du marché mondial du traitement de la maladie du greffon contre l'hôte (GvHD) fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.
Certains des principaux acteurs du marché opérant sur le marché sont Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Janssen Global Services, LLC, MALLINCKRODT PLC, Incyte., Sanofi, Alkem Laboratories Ltd. et Astellas Pharma Inc., entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS_
4.2 PORTER'S FIVE FORCES MODEL
5 PIPE LINE ANALYSIS OF GRAFT VERSUS HOST DISEASE MARKET
6 REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING INCIDENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT)
7.1.2 AWARENESS CAMPAIGNS AND PATIENT EDUCATION
7.1.3 ADVANCEMENTS IN TREATMENT OPTIONS
7.2 RESTRAINTS
7.2.1 HIGH COST OF MEDICATIONS AND SUPPORTIVE CARE
7.2.2 DISEASE HETEROGENEITY
7.3 OPPORTUNITIES
7.3.1 MARKET EXPANSION THROUGH STRATEGIC INITIATIVES AND PARTNERSHIP
7.3.2 GROWING PIPELINE OF INNOVATIVE DRUGS FOR GVHD TREATMENT
7.3.3 EMPOWERING PATIENT-CENTRIC APPROACH TO GVHD TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT REGULATIONS IN GVHD THERAPIES
7.4.2 SAFETY CONCERN AND COMPLEXITIES DURING TREATMENT
8 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 CHRONIC GVHD
8.2.1 CORTICOSTEROIDS
8.2.1.1 PREDNISOLONE
8.2.1.2 METHYLPREDNISOLONE
8.2.2 IMMUNOSUPPRESSIVE
8.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
8.2.2.2 METHOTREXATE (MTX)
8.2.2.3 IBRUTINIB
8.2.2.4 BELUMOSUDIL
8.2.2.5 RUXOLITINIB
8.2.2.6 ANTITHYMOCYTE GLOBULIN (ATG)
8.2.2.7 OTHERS
8.2.3 CALCINEURIN INHIBITORS
8.2.4 OTHERS
8.2.4.1 BRANDED
8.2.4.1.1 REZUROCK
8.2.4.1.2 IMBRUVICA
8.2.4.1.3 JAKAFI
8.2.4.2 GENERIC
8.3 ACUTE GVHD
8.3.1 CORTICOSTEROIDS
8.3.1.1 METHYLPREDNISOLONE
8.3.1.2 PREDNISOLONE
8.3.2 IMMUNOSUPPRESSIVE
8.3.2.1 MYCOPHENOLATE MOFETIL (MMF)
8.3.2.2 RUXOLITINIB
8.3.2.3 OTHERS
8.3.3 CALCINEURIN INHIBITORS
8.3.3.1 TACROLIMUS (TAC)
8.3.3.2 CYCLOSPORIN (CSA)
8.3.4 OTHERS
8.4 PROPHYLACTIC
8.4.1 CYCLOSPORIN (CSA)
8.4.2 METHOTREXATE (MTX)
8.4.3 TACROLIMUS (TAC)
8.4.4 METHYLPREDNISOLONE
8.4.5 OTHERS
8.4.5.1 GENERIC
8.4.5.2 BRANDED
8.4.5.2.1 ORENCIA
8.4.5.2.2 OTHERS
9 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INTRAVENOUS
9.4 TOPICAL
9.5 OTHERS
10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 CORTICOSTEROIDS
10.2.1.1 METHYLPREDNISOLONE
10.2.1.2 PREDNISOLONE
10.2.2 IMMUNOSUPPRESSIVE
10.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
10.2.2.2 METHOTREXATE (MTX)
10.2.2.3 IBRUTINIB
10.2.2.4 BELUMOSUDIL
10.2.2.5 RUXOLITINIB
10.2.2.6 ANTITHYMOCYTE GLOBULIN (ATG)
10.2.2.7 OTHERS
10.2.3 CALCINEURIN INHIBITORS
10.2.3.1 TACROLIMUS (TAC)
10.2.3.2 CYCLOSPORIN (CSA)
10.2.3.3 OTHERS
10.2.4 BRANDED
10.2.4.1 REZUROCK
10.2.4.2 IMBRUVICA
10.2.4.3 JAKAFI
10.2.4.4 ORENCIA
10.2.4.5 OTHERS
10.2.5 GENERIC
10.3 THERAPY
11 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE
11.1 OVERVIEW
11.2 ADULTS
11.3 PEDIATRIC
12 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER
12.1 OVERVIEW
12.2 FEMALE
12.3 MALE
13 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.2.1 PUBLIC
13.2.2 PRIVATE
13.3 TRANSPLANT CENTERS
13.4 INSTITUTES
13.5 SPECIALITY CENTERS
14 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 HOSPITAL PHARMACY
14.3.2 RETAIL PHARMACY
14.3.3 ONLINE PHARMACY
14.4 OTHERS
15 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 ITALY
15.3.4 U.K.
15.3.5 SPAIN
15.3.6 BELGIUM
15.3.7 RUSSIA
15.3.8 SWITZERLAND
15.3.9 DENMARK
15.3.10 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 AUSTRALIA
15.4.4 SOUTH KOREA
15.4.5 INDIA
15.4.6 MALAYSIA
15.4.7 SINGAPORE
15.4.8 PHILIPPINES
15.4.9 INDONESIA
15.4.10 REST OF ASIA PACIFIC
15.5 MIDDLE EAST AND AFRICA
15.5.1 SOUTH AFRICA
15.5.2 SAUDI ARABIA
15.5.3 U.A.E.
15.5.4 KUWAIT
15.5.5 BAHRAIN
15.5.6 REST OF MIDDLE EAST AND AFRICA
15.6 SOUTH AMERICA
15.6.1 BRAZIL
15.6.2 ARGENTINA
15.6.3 REST OF SOUTH AMERICA
16 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILES
18.1 BRISTOL-MYERS SQUIBB COMPANY
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 ABBVIE INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 JANSSEN GLOBAL SERVICES, LLC
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 MALLINCKRODT
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ALKEM LABORATORIES LTD.
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ASTELLAS PHARMA INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 INCYTE.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 SANOFI
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
TABLE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL ORAL IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL INTRAVENOUS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL TOPICAL IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL ADULTS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 35 GLOBAL FEMALE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 GLOBAL MALE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 38 LOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 40 GLOBAL TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 41 GLOBAL INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 GLOBAL SPECIALITY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 44 GLOBAL DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 47 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 48 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA IMMUNOSUPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 61 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 63 NORTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 64 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 65 NORTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 66 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 67 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 68 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 72 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 73 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 74 NORTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 75 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 76 NORTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 77 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 79 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 80 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 81 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 82 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 86 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 87 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 88 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 U.S. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 91 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 92 U.S. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 93 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 94 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 95 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 98 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 99 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 100 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 U.S. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 102 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 103 U.S. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 104 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 105 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 106 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 107 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 108 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 109 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 113 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 114 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 115 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 CANADA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 118 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 119 CANADA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 120 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 121 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 122 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 125 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 126 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 127 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 128 CANADA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 129 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 130 CANADA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 131 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 132 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 133 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 134 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 135 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 136 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 140 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 141 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 142 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 143 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 MEXICO ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 145 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 146 MEXICO IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 147 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 148 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 149 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 151 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 152 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 153 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 154 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 155 MEXICO HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 156 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 157 MEXICO RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 158 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 159 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 160 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 161 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 162 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 163 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 164 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 166 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 168 EUROPE CORTICOSTEROIDS GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 169 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 170 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 171 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 EUROPE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 173 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 174 EUROPE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 175 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 176 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 177 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 178 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 180 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 181 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 182 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 183 EUROPE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 184 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 185 EUROPE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 186 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 187 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 188 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 189 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 190 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 191 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 194 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 195 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 196 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 197 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 GERMANY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 200 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 201 GERMANY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 202 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 203 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 204 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 207 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 208 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 209 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 210 GERMANY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 211 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 212 GERMANY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 213 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 214 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 215 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 216 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 217 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 218 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 221 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 222 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 223 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 224 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 FRANCE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 227 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 228 FRANCE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 229 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 230 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 231 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 234 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 235 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 236 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 237 FRANCE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 238 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 239 FRANCE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 240 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 241 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 242 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 243 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 244 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 245 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 246 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 247 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 248 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 249 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 250 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 251 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 ITALY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 254 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 255 ITALY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 256 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 257 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 258 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 261 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 262 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 263 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 264 ITALY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 265 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 266 ITALY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 267 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 268 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 269 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 270 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 271 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 272 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 276 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 277 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 278 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 280 U.K. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 281 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 282 U.K. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 283 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 284 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 285 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 288 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 289 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 290 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 291 U.K. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 292 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 293 U.K. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 294 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 295 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 296 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 297 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 298 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 299 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 302 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 303 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 304 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 305 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 307 SPAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 308 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 309 SPAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 310 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 311 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 312 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 315 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 316 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 317 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 318 SPAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 319 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 320 SPAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 321 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 322 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 323 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 324 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 325 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 326 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 328 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 330 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 331 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 332 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 BELGIUM ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 335 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 336 BELGIUM IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 337 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 338 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 339 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 341 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 342 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 343 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 344 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 345 BELGIUM HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 346 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 347 BELGIUM RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 348 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 349 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 350 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 351 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 352 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 353 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 354 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 356 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 357 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 358 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 359 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 360 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 RUSSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 362 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 363 RUSSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 364 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 365 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 366 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 367 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 368 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 369 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 370 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 371 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 372 RUSSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 373 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 374 RUSSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 375 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 376 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 377 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 378 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 379 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 380 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 381 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 382 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 383 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 384 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 385 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 386 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 387 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 388 SWITZERLAND ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 389 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 390 SWITZERLAND IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 391 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 392 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 393 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 394 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 395 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 396 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 397 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 398 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 399 SWITZERLAND HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 400 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 401 SWITZERLAND RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 402 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 403 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 404 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 405 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 406 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 407 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 408 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 409 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 410 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 411 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 412 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 413 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 414 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 415 DENMARK ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 416 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 417 DENMARK IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 418 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 419 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 420 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 421 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 422 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 423 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 424 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 425 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 426 DENMARK HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 427 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 428 DENMARK RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 429 REST OF EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 430 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 431 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 432 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 433 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 434 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 435 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 436 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 437 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 438 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 440 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 441 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 442 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 443 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 444 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 445 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 446 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 447 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 448 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 449 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 450 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 451 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 452 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 453 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 454 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 455 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 456 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 457 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 458 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 459 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 460 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 461 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 462 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 463 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 464 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 465 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 466 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 467 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 468 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 469 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 470 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 471 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 472 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 473 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 474 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 475 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 476 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 477 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 478 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 479 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 480 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 481 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 482 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 483 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 484 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 485 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 486 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 487 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 488 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 489 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 490 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 491 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 492 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 493 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 494 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 495 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 496 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 497 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 498 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 499 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 500 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 501 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 502 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 503 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 504 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 505 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 506 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 507 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 508 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 509 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 510 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 511 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 512 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 513 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 514 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 515 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 516 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 517 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 518 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 519 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 520 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 521 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 522 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 523 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 524 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 525 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 526 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 527 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 528 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 529 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 530 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 531 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 532 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 533 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 534 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 535 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 536 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 537 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 538 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 539 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 540 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 541 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 542 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 543 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 544 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 545 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 546 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 547 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 548 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 549 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 550 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 551 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 552 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 553 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 554 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 555 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 556 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 557 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 558 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 559 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 560 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 561 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 562 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 563 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 564 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 565 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 566 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 567 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 568 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 569 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 570 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 571 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 572 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 573 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 574 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 575 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 576 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 577 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 578 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 579 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 580 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 581 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 582 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 583 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 584 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 585 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 586 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 587 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 588 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 589 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 590 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 591 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 592 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 593 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 594 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 595 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 596 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 597 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 598 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 599 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 600 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 601 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 602 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 603 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 604 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 605 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 606 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 607 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 608 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 609 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 610 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 611 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 612 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 613 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 614 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 615 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 616 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 617 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 618 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 619 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 620 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 621 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 622 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 623 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 624 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 625 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 626 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 627 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 628 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 629 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 630 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 631 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 632 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 633 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 634 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 635 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 636 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 637 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 638 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 639 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 640 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 641 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 642 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 643 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 644 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 645 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 646 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 647 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 648 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 649 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 650 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 651 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 652 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 653 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 654 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 655 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 656 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 657 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 658 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 659 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 660 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 661 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 662 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 663 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 664 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 665 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 666 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 667 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 668 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 669 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 670 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 671 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 672 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 673 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 674 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 675 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 676 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 677 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 678 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 679 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 680 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 681 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 682 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 683 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 684 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 685 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 686 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 687 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 688 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 689 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 690 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 691 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 692 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 693 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 694 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 695 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 696 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 697 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 698 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 699 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 700 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 701 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 702 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 703 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 704 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 705 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 706 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 707 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 708 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 709 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 710 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 711 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 712 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 713 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 714 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 715 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 716 MIDDLE EAST AND AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 717 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 718 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 719 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 720 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 721 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 722 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 723 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 724 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 725 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 726 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 727 MIDDLE EAST AND AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 728 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 729 MIDDLE EAST AND AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 730 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 731 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 732 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 733 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 734 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 735 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 736 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 737 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 738 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 739 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 740 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 741 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 742 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 743 SOUTH AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 744 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 745 SOUTH AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 746 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 747 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 748 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 749 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 750 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 751 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 752 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 753 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 754 SOUTH AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 755 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 756 SOUTH AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 757 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 758 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 759 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 760 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 761 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 762 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 763 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 764 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 765 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 766 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 767 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 768 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 769 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 770 SAUDI ARABIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 771 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 772 SAUDI ARABIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 773 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 774 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 775 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 776 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 777 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 778 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 779 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 780 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 781 SAUDI ARABIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 782 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 783 SAUDI ARABIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 784 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 785 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 786 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 787 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 788 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 789 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 790 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 791 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 792 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 793 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 794 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 795 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 796 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 797 U.A.E. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 798 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 799 U.A.E. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 800 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 801 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 802 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 803 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 804 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 805 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 806 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 807 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 808 U.A.E. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 809 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 810 U.A.E. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 811 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 812 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 813 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 814 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 815 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 816 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 817 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 818 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 819 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 820 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 821 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 822 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 823 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 824 KUWAIT ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 825 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 826 KUWAIT IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 827 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 828 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 829 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 830 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 831 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 832 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 833 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 834 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 835 KUWAIT HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 836 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 837 KUWAIT RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 838 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 839 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 840 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 841 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 842 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 843 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 844 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 845 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 846 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 847 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 848 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 849 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 850 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 851 BAHRAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 852 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 853 BAHRAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 854 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 855 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 856 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 857 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 858 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 859 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 860 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 861 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 862 BAHRAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 863 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 864 BAHRAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 865 REST OF MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 866 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 867 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 868 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 869 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 870 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 871 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 872 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 873 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 874 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 875 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 876 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 877 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 878 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 879 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 880 SOUTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 881 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 882 SOUTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 883 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 884 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 885 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 886 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 887 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 888 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 889 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 890 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 891 SOUTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 892 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 893 SOUTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 894 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 895 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 896 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 897 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 898 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 899 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 900 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 901 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 902 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 903 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 904 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 905 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 906 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 907 BRAZIL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 908 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 909 BRAZIL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 910 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 911 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 912 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 913 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 914 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 915 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 916 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 917 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 918 BRAZIL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 919 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 920 BRAZIL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 921 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 922 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 923 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 924 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 925 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 926 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 927 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 928 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 929 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 930 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 931 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 932 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 933 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 934 ARGENTINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 935 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 936 ARGENTINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 937 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 938 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2022-2031 (USD THOUSAND)
TABLE 939 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 940 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 941 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 942 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 943 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 944 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 945 ARGENTINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 946 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 947 ARGENTINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 948 REST OF SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE GROWING NUMBER OF STEM CELL TRANSPLANTATIONS IS DRIVING THE GROWTH OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING REGION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
FIGURE 16 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TYPE 2023
FIGURE 17 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY METHOD OF ADMINISTRATION, 2023
FIGURE 21 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY METHOD OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY METHOD OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 23 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY METHOD OF ADMINISTRATION, LIFELINE CURVE
FIGURE 24 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY TREATMENT, 2023
FIGURE 25 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY TREATMENT, CAGR (2024-2031)
FIGURE 27 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY TREATMENT, LIFELINE CURVE
FIGURE 28 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY AGE, 2023
FIGURE 29 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY AGE, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY AGE, CAGR (2024-2031)
FIGURE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY AGE, LIFELINE CURVE
FIGURE 32 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY GENDER, 2023
FIGURE 33 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY GENDER, CAGR (2024-2031)
FIGURE 35 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET : BY GENDER, LIFELINE CURVE
FIGURE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY END USER 2023
FIGURE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 38 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: END USER, CAGR (2024-2031)
FIGURE 39 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET END USER, LIFELINE CURVE
FIGURE 40 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2023
FIGURE 41 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 42 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 43 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 45 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 46 NORTH AMERICA GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 47 EUROPE GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 48 AISA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
